ArticleProceedings of the National Academy of Sciences of the United States of America1988
Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 157 citations in OpenAlex.
- Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.The Cochrane database of systematic reviews · 2016Pooled it
- Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways.BMC medical genetics · 2014Pooled it
- Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease.Scientific reports · 2017Article
- Genetics of diabetic nephropathy: a long road of discovery.Current diabetes reports · 2015Review
- A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2013Article
- A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney.Clinical and experimental nephrology · 2012Article
- Importance of anemia in the chronic Cardiorenal syndrome: effects on renal function after heart transplantation.Medical science monitor : international medical journal of experimental and clinical research · 2012Article
- Animal models of cardiorenal syndrome: a review.Heart failure reviews · 2012Review
- Anemia, diabetes, and chronic kidney disease.Diabetes care · 2009Review
- Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Anemia and diabetic nephropathy.Current diabetes reports · 2006Review
- r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline.BMC nephrology · 2003Article
- Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats.Gene therapy · 2001Article
- Myoblast transfer of human erythropoietin gene in a mouse model of renal failure.The Journal of clinical investigation · 1995Article
- Effect of lidocaine on the hematopoietic properties of recombinant human erythropoietin in the uremic rat.Pediatric nephrology (Berlin, Germany) · 1994Article
- Erythropoietin therapy in patients with chronic renal failure.The Western journal of medicine · 1992Review
- Prevention of 11-deoxycorticosterone-salt-induced glomerular hypertrophy and glomerulosclerosis by dietary phosphate binder.The American journal of pathology · 1990Article
- Review
- Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.Drug safetyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Chronic renal disease is frequently characterized by anemia, which may modify systemic and renal hemodynamics. In adult Munich-Wistar rats, the mild anemia (hematocrit, approximately equal to 42 vol/dl) that accompanies five-sixths nephrectomy was either made more severe (approximately equal to 30 vol/dl) by feeding a low iron diet or prevented (approximately equal to 50 vol/dl) by administration of recombinant human erythropoietin (r-HuEpo). In functional studies performed 4 weeks after renal ablation, untreated rats exhibited mild anemia with systemic hypertension and elevation of the single nephron glomerular filtration rate due to glomerular capillary hyperperfusion and hypertension. Preventing anemia with r-HuEpo worsened systemic and glomerular hypertension, effects largely obviated by induction of more marked anemia with the low iron diet. Untreated rats followed for 6 weeks postablation exhibited progressive proteinuria and sclerosis involving 12% of glomeruli, contrasted with 33% in rats given r-HuEpo. Even after 12 weeks, sclerosis involved only 6% of glomeruli in rats with more severe anemia but progressed to 30% in untreated rats. Thus, anemia limits systemic and glomerular hypertension and glomerular injury, whereas its prevention by r-HuEpo severely accelerates hemodynamically mediated glomerular injury in this model. These results suggest that anemia is a hemodynamically favorable adaptation to chronic renal disease and that its overly vigorous correction may have adverse renal hemodynamic and structural consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.